New avenues for second-line treatment of metastatic non-small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

New avenues for second-line treatment of metastatic non-small-cell lung cancer.

New avenues for second-line treatment of metastatic non-small-cell lung cancer.

http://www.wikidata.org/entity/Q37357304

about

Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.Thymidylate synthase inhibitors for non-small cell lung cancer.Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel.

P2860

Q30538788-3E8326D5-8C61-49D9-9BAE-EB97DF0C1E8E Q37929783-3FAE72E0-C674-4FB4-917C-BD028E34F37E Q41002305-C6569239-69DC-470A-9789-B429A9BE9791

P2860

New avenues for second-line treatment of metastatic non-small-cell lung cancer.

http://www.wikidata.org/entity/Q37357304

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

New avenues for second-line treatment of metastatic non-small-cell lung cancer.

@en

New avenues for second-line treatment of metastatic non-small-cell lung cancer.

@nl

type

label

New avenues for second-line treatment of metastatic non-small-cell lung cancer.

@en

New avenues for second-line treatment of metastatic non-small-cell lung cancer.

@nl

prefLabel

New avenues for second-line treatment of metastatic non-small-cell lung cancer.

@en

New avenues for second-line treatment of metastatic non-small-cell lung cancer.

@nl

P1433

Q37357304-C2365636-9DEF-457B-ACC5-2C5E9A483197

P1476

Q37357304-27BC0494-5C8C-4387-93D1-E9FA7CBD2A2A

P2093

Q37357304-0BD35A86-4018-42A5-88D5-20EDB718AE03

Q37357304-25C6D54A-4992-4745-A40E-5766F0F5E15E

Q37357304-2C8A1FD9-1C38-40A3-870D-CE920379C332

Q37357304-360F0252-9359-4488-922F-1928603C5062

Q37357304-43514B6C-9CCE-4B48-BF32-F528242779F2

Q37357304-B72806E3-6A8B-4CE3-A313-20AD676F99F9

Q37357304-BB22D3A4-9C60-4E04-AD98-3715B50C0E51

Q37357304-C264F6D4-A516-4A8B-B0F5-1251137E71FE

Q37357304-C558B52F-F79E-42EA-8A0F-82F0EEFB4B9C

Q37357304-DE8B86BA-8B34-4EBE-86DF-D2E13F4378AE

P2860

Q37357304-091ED980-C339-40C1-932A-FF4CE9FC0B6F

Q37357304-0C24F162-8EF9-4419-AD62-72D1F2662794

Q37357304-10E01A81-CB55-41F6-9AB9-324A9AE47951

Q37357304-14F951C4-3023-4D0B-8A7B-4454D4CC4F6A

Q37357304-24251EFE-F305-4629-9599-2C9612D81867

Q37357304-292AFBDD-0EC9-47F9-AB11-7C4650BF077A

Q37357304-2C293009-A1CD-4C1F-878C-485A729B96D0

Q37357304-2FD664E7-2196-4F43-8D49-971C2D35E67C

Q37357304-4156E04D-BB94-49D4-ADD9-32E36EFD577D

Q37357304-475449F3-EEF5-4215-8CB2-A9A5546502F8

P304

Q37357304-AC24EE46-B1A7-4C71-B927-8A5CE2D88C03

P31

Q37357304-2010BF1D-9F67-4624-AFD6-9778FD33523A

P356

Q37357304-F02942AE-8CD7-4ECA-8155-23212B1FBA48

P433

Q37357304-47121925-CE24-4C71-B9D3-7718C8C8C45C

P478

Q37357304-5C998EC4-C3D3-485B-A177-40A138FBD053

P50

Q37357304-57128419-A566-4B63-B347-42BB2B98C6B1

P577

Q37357304-CA89BD43-DF69-4BE1-A8CB-A5359D3F099E

P698

Q37357304-4AFE629A-2074-4050-93CE-60FA03D7A11B

P921

Q37357304-C67898BA-E5B6-4927-BA8C-9C673CAF3CBE

P356

14737140.9.1.115

P1433

Expert Review of Anticancer Therapy

P1476

New avenues for second-line treatment of metastatic non-small-cell lung cancer.

@en

P2093

Antonio Rossi

http://www.w3.org/2001/XMLSchema#string

Ciro Guerriero

http://www.w3.org/2001/XMLSchema#string

Clorinda Schettino

http://www.w3.org/2001/XMLSchema#string

Dario Nicolella

http://www.w3.org/2001/XMLSchema#string

Emanuela Rossi

http://www.w3.org/2001/XMLSchema#string

Giovanni Palazzolo

http://www.w3.org/2001/XMLSchema#string

Giuseppe Colantuoni

http://www.w3.org/2001/XMLSchema#string

Marianna Bareschino

http://www.w3.org/2001/XMLSchema#string

Marianna Luciana Ferrara

http://www.w3.org/2001/XMLSchema#string

Marzia Falanga

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Erlotinib in previously treated non-small-cell lung cancer

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

What is the evidence that tumors are angiogenesis dependent?

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer.

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

P304

115-124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.9.1.115

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Cesare Gridelli

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19105711

http://www.w3.org/2001/XMLSchema#string

P921